BCL2 and plasma cell myeloma: In our previous study, we showed that the SK2 inhibitor (ABC294640) decreased multiple myeloma cell proliferation in vitro and exhibited significant anti‐myeloma efficacy in vivo.4 In the present study, we investigated the combinatorial effects of ABC294640 and Bcl‐2 inhibitor (ABT‐199) on MM cells.